Published in Antimicrob Agents Chemother on April 01, 1991
Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother (1993) 6.28
The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J Bacteriol (1992) 4.99
Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob Agents Chemother (1992) 3.63
Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol (1994) 3.61
Current perspectives on glycopeptide resistance. Clin Microbiol Rev (1995) 2.99
Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol (1998) 2.72
Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1993) 2.61
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Emergence of vancomycin-resistant enterococci. Emerg Infect Dis (2001) 2.48
Characterization of vanY, a DD-carboxypeptidase from vancomycin-resistant Enterococcus faecium BM4147. Antimicrob Agents Chemother (1992) 1.73
Recovery of vancomycin-resistant gram-positive cocci from pediatric liver transplant recipients. J Clin Microbiol (1991) 1.69
Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.53
Vancomycin resistance in Enterococcus gallinarum. Antimicrob Agents Chemother (1992) 1.32
Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother (1992) 1.29
In vitro activity of vancomycin against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother (1993) 1.23
Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium. Antimicrob Agents Chemother (1992) 1.22
Constitutively vancomycin-resistant Enterococcus faecium resistant to synergistic beta-lactam combinations. Antimicrob Agents Chemother (1993) 1.18
Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis. Antimicrob Agents Chemother (1999) 1.14
Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium. Antimicrob Agents Chemother (1994) 1.08
Penicillin tolerance and modification of lipoteichoic acid associated with expression of vancomycin resistance in VanB-type Enterococcus faecium D366. Antimicrob Agents Chemother (1996) 0.98
Differential susceptibilities of enterococcal species to elfamycin antibiotics. J Clin Microbiol (1994) 0.85
Chlorhexidine Induces VanA-Type Vancomycin Resistance Genes in Enterococci. Antimicrob Agents Chemother (2016) 0.83
Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates. Curr Microbiol (2008) 0.83
Genetic basis for vancomycin-enhanced cephalosporin susceptibility in vancomycin-resistant enterococci revealed using counterselection with dominant-negative thymidylate synthase. Antimicrob Agents Chemother (2013) 0.82
Simple test of synergy between ampicillin and vancomycin for resistant strains of Enterococcus faecium. J Clin Microbiol (1994) 0.82
Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrob Agents Chemother (1994) 0.79
Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis (1997) 0.77
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother (1989) 5.28
Self-transferable plasmids determining the hemolysin and bacteriocin of Streptococcus faecalis var. zymogenes. J Bacteriol (1975) 5.04
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis (1989) 4.34
Problems with the disk diffusion test for detection of vancomycin resistance in enterococci. J Clin Microbiol (1989) 3.97
Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin Microbiol Rev (1990) 3.82
Use of penicillin-binding proteins for the identification of enterococci. J Gen Microbiol (1986) 2.87
Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob Agents Chemother (1990) 2.70
Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother (1991) 2.31
Inducible, transferable resistance to vancomycin in Enterococcus faecium, D399. J Antimicrob Chemother (1989) 1.87
Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiol Infect (1989) 1.05
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet (1997) 4.77
Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia. J Infect Dis (1985) 4.52
High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother (1996) 4.04
Dissemination of the novel plasmid-mediated beta-lactamase CTX-1, which confers resistance to broad-spectrum cephalosporins, and its inhibition by beta-lactamase inhibitors. Antimicrob Agents Chemother (1988) 3.57
Mediastinitis due to multiple resistant Corynebacterium xerosis. Clin Infect Dis (1993) 3.14
Use of penicillin-binding proteins for the identification of enterococci. J Gen Microbiol (1986) 2.87
One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin. J Gen Microbiol (1985) 2.73
Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob Agents Chemother (1990) 2.70
Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem. Antimicrob Agents Chemother (1991) 2.68
Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases. Antimicrob Agents Chemother (1986) 2.63
Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (1997) 2.50
In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. J Infect Dis (1989) 2.27
Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology (2008) 2.17
Acquisition of five high-Mr penicillin-binding protein variants during transfer of high-level beta-lactam resistance from Streptococcus mitis to Streptococcus pneumoniae. J Bacteriol (1998) 2.16
Susceptibility of Nocardia asteroides to 46 antibiotics, including 22 beta-lactams. Antimicrob Agents Chemother (1983) 2.15
Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother (1994) 2.13
Nucleotide sequence of the SHV-5 beta-lactamase gene of a Klebsiella pneumoniae plasmid. Antimicrob Agents Chemother (1990) 2.08
Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium. J Bacteriol (1996) 2.08
Comparison of vancomycin-inducible proteins from four strains of Enterococci. FEMS Microbiol Lett (1990) 2.01
Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother (1993) 1.95
Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. J Infect Dis (2000) 1.86
Presence of an additional penicillin-binding protein in methicillin-resistant Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus simulans with a low affinity for methicillin, cephalothin, and cefamandole. Antimicrob Agents Chemother (1990) 1.83
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother (1999) 1.81
Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance. Antimicrob Agents Chemother (1990) 1.75
Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis (1995) 1.74
Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid. Antimicrob Agents Chemother (1993) 1.73
Pupil-sparing oculomotor nerve palsy due to midbrain infarction. Arch Neurol (1991) 1.63
Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium. J Biol Chem (2000) 1.62
Molecular evolution of ubiquitous beta-lactamases towards extended-spectrum enzymes active against newer beta-lactam antibiotics. Mol Microbiol (1990) 1.55
Penicillin-binding protein 5 and expression of ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother (2001) 1.52
Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob Agents Chemother (1991) 1.52
Characterization of nutritionally variant streptococci by biochemical tests and penicillin-binding proteins. J Clin Microbiol (1985) 1.51
Analysis of peptidoglycan precursors in vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.50
Characterization of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals. Vigil'Roc Study Group. J Antimicrob Chemother (1993) 1.50
Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance. J Infect Dis (1998) 1.48
Atypical deep peroneal neuropathy in presence of accessory deep peroneal nerve. J Neurol Neurosurg Psychiatry (1970) 1.47
In-vitro susceptibility of Nocardia asteroides to 21 beta-lactam antibiotics, in combination with three beta-lactamase inhibitors, and its relationship to the beta-lactamase content. J Antimicrob Chemother (1985) 1.46
The new quinolones and their combinations with other agents for therapy of severe infections. J Antimicrob Chemother (1986) 1.46
Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase. Antimicrob Agents Chemother (1990) 1.45
Picornavirus-like crystals in subacute polymyositis. Neurology (1970) 1.44
When is myokymia neuromyotonia? Muscle Nerve (2001) 1.43
Electrodiagnosis of infantile botulism. J Child Neurol (1994) 1.41
Mechanisms of resistance to quinolones. Drugs (1993) 1.41
Pick's disease: a case clinically resembling amyotrophic lateral sclerosis. Neurology (1991) 1.40
Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother (2013) 1.40
Sch 34343 activity against streptococci and beta-lactam-resistant Enterobacteriaceae. J Antimicrob Chemother (1985) 1.39
Persistent unilateral tibialis anterior muscle hypertrophy with complex repetitive discharges and myalgia: report of two unique cases and response to botulinum toxin. Neurology (1992) 1.39
Intrapontine generation of myokymia in multiple sclerosis. Muscle Nerve (1993) 1.39
Guillain-Barre syndrome. Another immune-mediated disease with a predilection for young women? W V Med J (1989) 1.38
Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin Microbiol Infect (2006) 1.38
Amnesia due to fornix infarction. Stroke (2000) 1.37
Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1991) 1.37
In vivo and in vitro emergence of simultaneous resistance to both beta-lactam and aminoglycoside antibiotics in a strain of Serratia marcescens. Ann Microbiol (Paris) (1983) 1.36
Penicillin-resistant and penicillin-tolerant mutants of group A Streptococci. Antimicrob Agents Chemother (1982) 1.36
In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x. Antimicrob Agents Chemother (1996) 1.35
Hereditary aspects of accessory deep peroneal nerve. J Neurol Neurosurg Psychiatry (1973) 1.34
Carbapenem resistance in a clinical isolate of Citrobacter freundii. Antimicrob Agents Chemother (1997) 1.34
Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital. J Clin Microbiol (2000) 1.33
Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some beta-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam). Antimicrob Agents Chemother (1986) 1.32
Vancomycin resistance in Enterococcus gallinarum. Antimicrob Agents Chemother (1992) 1.32
Identification of coagulase-negative staphylococci by electrophoretic profile of total proteins and analysis of penicillin-binding proteins. J Clin Microbiol (1990) 1.32
Dapsone motor neuropathy--an axonal disease. Neurology (1976) 1.30
Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother (1992) 1.29
Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium. Antimicrob Agents Chemother (2001) 1.28
Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics. J Bacteriol (1996) 1.28
Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci. J Antimicrob Chemother (1990) 1.28
Physiological properties of penicillin-binding proteins in group A streptococci. Antimicrob Agents Chemother (1981) 1.26
Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae. Antimicrob Agents Chemother (1991) 1.24
Median--ulnar nerve communications and carpal tunnel syndrome. J Neurol Neurosurg Psychiatry (1977) 1.24
In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis (1999) 1.22
Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrob Agents Chemother (1993) 1.19
A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics. Antimicrob Agents Chemother (1997) 1.19
Acute trimethyltin limbic-cerebellar syndrome. Neurology (1987) 1.19
A silent carbapenemase gene in strains of Bacteroides fragilis can be expressed after a one-step mutation. FEMS Microbiol Lett (1992) 1.18
Correlation of penicillin-induced lysis of Enterococcus faecium with saturation of essential penicillin-binding proteins and release of lipoteichoic acid. Antimicrob Agents Chemother (1990) 1.17
Inducible and constitutive expression of resistance to glycopeptides and vancomycin dependence in glycopeptide-resistant Enterococcus avium. Antimicrob Agents Chemother (1995) 1.14
Genetic variation and inferences about perceived taste intensity in mice and men. Physiol Behav (2000) 1.13
Native valve endocarditis caused by Staphylococcus capitis. Eur J Clin Microbiol Infect Dis (1993) 1.13
Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill (2008) 1.12
The intramuscular nerve action potential. J Neurol Neurosurg Psychiatry (1969) 1.12
Diffusion of beta-lactam antibiotics into proteoliposomes reconstituted with outer membranes of isogenic imipenem-susceptible and -resistant strains of Enterobacter cloacae. J Gen Microbiol (1992) 1.12
Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-beta-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366. FEMS Microbiol Lett (1992) 1.11
Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis. Antimicrob Agents Chemother (1995) 1.11
Subacute focal adenovirus encephalitis. J Neuropathol Exp Neurol (1973) 1.10
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother (1994) 1.10
Acute type II myofiber atrophy in critical illness. Neurology (1996) 1.09
Biological and immunological comparisons of Enterobacter cloacae and Escherichia coli porins. FEMS Microbiol Lett (1995) 1.09
Development of resistance to beta-lactam antibiotics with special reference to third-generation cephalosporins. J Antimicrob Chemother (1984) 1.09
Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type. Biochem J (1996) 1.09
In vitro activities of 15 oral beta-lactams against Klebsiella pneumoniae harboring new extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1990) 1.07
Resistance exercise training modulates acute gene expression during human skeletal muscle hypertrophy. J Appl Physiol (1985) (2014) 1.06
Familial parkinsonism, apathy, weight loss, and central hypoventilation: successful long-term management. Neurology (1988) 1.05
Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology (2001) 1.05
Electromyographic changes of brachial plexus root avulsions. J Neurosurg (1969) 1.03
Vancomycin dependence in a vanA-producing Enterococcus avium strain with a nonsense mutation in the natural D-Ala-D-Ala ligase gene. Antimicrob Agents Chemother (1997) 1.03
A model system to demonstrate that beta-lactamase-associated antibiotic trapping could be a potential means of resistance. J Infect Dis (1983) 1.02
Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother (2000) 1.02